Main Page

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: <table id="tableColumnsMainPage" style="width:100%;border:2px solid #ddd;border-collapse: collapse;table-layout: fixed; "> <tr><td colspan='4' style="background:#F5F5FC;border:1px solid #d...)
Line 7: Line 7:
<tr>
<tr>
<th style="padding: 10px;background-color: #33ff7b">Selected Pages</th>
<th style="padding: 10px;background-color: #33ff7b">Selected Pages</th>
-
<th style="padding: 10px;background-color: #f1b840">Art on Science</th>
+
<th style="padding: 10px;background-color: #dae4d9">Art on Science</th>
-
<th style="padding: 10px;background-color: #dae4d9">Journals</th>
+
<th style="padding: 10px;background-color: #f1b840">Journals</th>
<th style="padding: 10px;background-color: #dae4d9">Education</th>
<th style="padding: 10px;background-color: #dae4d9">Education</th>
</tr>
</tr>

Revision as of 12:02, 18 October 2018

Welcome to Proteopedia
ISSN 2310-6301 The free, collaborative 3D-encyclopedia of proteins & other molecules

Selected Pages Art on Science Journals Education
About this image
Self-assembling Nano-Cages

Huddy, Hsia, Kibler, Xu & 27 others in the Nobel Prize winning group of David Baker have designed standardized protein building blocks that self assemble into a wide range of nanostructures. The building blocks attach to each other at engineered sites and angles, and come in various sizes.

>>> Get a quick overview! >>>

About this image
Opening a Gate to Human Health

by Alice Clark (PDBe)
In the 1970s, an exciting discovery of a family of medicines was made by the Japanese scientist Satoshi Ōmura. One of these molecules, ivermectin, is shown in this artwork bound in the ligand binding pocket of the Farnesoid X receptor, a protein which helps regulate cholesterol in humans. This structure showed that ivermectin induced transcriptional activity of FXR and could be used to regulate metabolism.

>>> Visit this page >>>

About this image
Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases.

IB Tomasic, MC Metcalf, AI Guce, NE Clark, SC Garman. J. Biol. Chem. 2010 doi: 10.1074/jbc.M110.118588
The human lysosomal enzymes α-galactosidase and α-N-acetylgalactosaminidase share 46% amino acid sequence identity and have similar folds. Using a rational protein engineering approach, we interconverted the enzymatic specificity of α-GAL and α-NAGAL. The engineered α-GAL retains the antigenicity but has acquired the enzymatic specificity of α-NAGAL. Conversely, the engineered α-NAGAL retains the antigenicity but has acquired the enzymatic specificity of the α-GAL enzyme. Comparison of the crystal structures of the designed enzyme to the wild-type enzymes shows that active sites superimpose well, indicating success of the rational design. The designed enzymes might be useful as non-immunogenic alternatives in enzyme replacement therapy for treatment of lysosomal storage disorders such as Fabry disease.

>>> Visit this I3DC complement >>>

About this image
Transport of Drugs & Nutrients

Above is a transmembrane protein that takes up, into your intestinal cells, orally consumed peptide nutrients and drugs. Its lumen-face (shown above) opens and binds peptide or drug, then closes, while its cytoplasmic face (opposite end from the above) opens to release its cargo into the intestinal cell, which passes it on into the blood circulation.

>>> See more animations and explanation >>>

Proteopedia Page Contributors and Editors (what is this?)

Joel L. Sussman, Jaime Prilusky

Personal tools